0001178913-23-000242.txt : 20230124
0001178913-23-000242.hdr.sgml : 20230124
20230124102100
ACCESSION NUMBER: 0001178913-23-000242
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230119
FILED AS OF DATE: 20230124
DATE AS OF CHANGE: 20230124
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: aMoon Growth Fund Limited Partnership
CENTRAL INDEX KEY: 0001744099
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39279
FILM NUMBER: 23546232
BUSINESS ADDRESS:
STREET 1: 34 YERUSHALAYIM RD.
CITY: RAANANA
STATE: L3
ZIP: 4350110
BUSINESS PHONE: 972(73)3989560
MAIL ADDRESS:
STREET 1: 34 YERUSHALAYIM RD.
CITY: RAANANA
STATE: L3
ZIP: 4350110
FORMER NAME:
FORMER CONFORMED NAME: aMoon 2 Fund Limited Partnership
DATE OF NAME CHANGE: 20180620
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schindel Yair Chaim
CENTRAL INDEX KEY: 0001823758
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39279
FILM NUMBER: 23546231
MAIL ADDRESS:
STREET 1: YERUSHALAYIM ROAD 34
STREET 2: BEIT GAMLA ENTRANCE B
CITY: RA'ANANA
STATE: L3
ZIP: 4350110
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Old Ayala, Inc
CENTRAL INDEX KEY: 0001797336
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 823578375
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1313 N. MARKET STREET
STREET 2: SUITE 5100
CITY: WILMINGTON
STATE: DE
ZIP: 19801
BUSINESS PHONE: (857) 444-0553
MAIL ADDRESS:
STREET 1: 1313 N. MARKET STREET
STREET 2: SUITE 5100
CITY: WILMINGTON
STATE: DE
ZIP: 19801
FORMER COMPANY:
FORMER CONFORMED NAME: Ayala Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20191218
4
1
zk2329064.xml
X0306
4
2023-01-19
1
0001797336
Old Ayala, Inc
AYLA
0001744099
aMoon Growth Fund Limited Partnership
34 YERUSHALAIM ROAD
BEIT GAMLA, 6TH FLOOR
RAANANA
L3
4350110
ISRAEL
0
0
1
0
0001823758
Schindel Yair Chaim
34 YERUSHALAIM ROAD
BEIT GAMLA, 6TH FLOOR
RAANANA
L3
4350110
ISRAEL
0
0
0
1
shareholder of 10% holder
Common Stock
2023-01-19
4
D
0
2991473
D
0
D
This Form 4 reports securities disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated October 18, 2022, by and among Ayala Pharmaceuticals, Inc. ("Ayala"), Advaxis, Inc. ("Advaxis"), and DOE Merger Sub, Inc., a wholly owned subsidiary of Advaxis (the "Merger Agreement"). The acquisition is more fully described in Ayala's definitive proxy statement filed with the Securities and Exchange Commission on December 12, 2022. In accordance with the terms of the Merger Agreement, upon the consummation of the merger on January 19, 2023, each share of Ayala's common stock was cancelled and converted into the right to receive shares of Advaxis common stock based on the exchange ratio set forth therein.
The reported shares were held of record by aMoon Growth Fund Limited Partnership ("aMoon Growth Fund"). aMoon Growth Fund G.P. Limited Partnership ("aMoon Growth Fund G.P.") is the sole General Partner of aMoon Growth Fund and aMoon General Partner Ltd. ("aMoon General Partner") is the sole General Partner of aMoon Growth Fund G.P. Dr. Yair Schindel is the sole shareholder of aMoon General Partner. By virtue of such relationships, aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel may have been deemed to have shared voting and investment power with respect to the shares held of record by aMoon Growth Fund. Each of aMoon Growth Fund G.P., aMoon General Partner and Dr. Schindel disclaims beneficial ownership of the shares held by aMoon Growth Fund except to the extent of its or his pecuniary interest therein, if any.
/s/ Yair Schindel, the sole shareholder of aMoon General Partner Ltd., the sole General Partner of aMoon Growth Fund G.P. Limited Partnership, the sole General Partner of aMoon Growth Fund, Limited Partnership
2023-01-24
/s/ Yair Schindel
2023-01-24